KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Share-based Compensation (2016 - 2025)

Arbutus Biopharma's Share-based Compensation history spans 13 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 41.53% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $7.3 million, down 19.32%, while the annual FY2024 figure was $9.0 million, 3.39% down from the prior year.
  • Share-based Compensation for Q3 2025 was $1.3 million at Arbutus Biopharma, up from $864000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.6 million in Q1 2025 and bottomed at $864000.0 in Q2 2025.
  • The 5-year median for Share-based Compensation is $1.7 million (2022), against an average of $2.0 million.
  • The largest YoY upside for Share-based Compensation was 76.96% in 2025 against a maximum downside of 72.83% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.4 million in 2021, then increased by 16.49% to $1.7 million in 2022, then rose by 3.36% to $1.7 million in 2023, then dropped by 5.28% to $1.6 million in 2024, then fell by 22.61% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Share-based Compensation are $1.3 million (Q3 2025), $864000.0 (Q2 2025), and $3.6 million (Q1 2025).